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Abstract
Purpose: There is limited information regarding the utility of Samarium-153 lexidronam 
(Quadramet) in the setting of men with prostate cancer status post radical prostatectomy (RP), who 
develop biochemical failure with no clinical evidence of osseous metastases.
Methods and Materials: Trial NRG Oncology RTOG 0622 is a single-arm Phase II trial that 
enrolled men with pT2-T4, N0–1, M0 prostate cancer status post RP, who meet at least one of 
these biochemical failure criteria: (1) PSA >1.0ng/ml; (2) PSA >0.2ng/ml if Gleason score of 9–
10; or (3) PSA >0.2ng/ml if N1. Patients received Samarium-153 (2.0mCi/kg IV x 1) followed by 
salvage external beam radiation therapy (EBRT) to the prostatic fossa (64.8–70.2Gy in 1.8Gy 
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daily fractions). No ADT was allowed. The primary objective was PSA response within 12 weeks 
of receiving Samarium-153. The secondary objectives were to (1) assess the completion rate for 
the regimen of Samarium-153 and EBRT, (2) evaluate the hematological toxicity and other adverse 
events (AE) at 12 and 24 weeks, and (3) freedom from progression (FFP) rate at 2 years.
Results: A total of 60 enrolled eligible patients were included in this analysis. Median follow up 
was 3.97 years. PSA response was achieved in 7/52 (13.5%) evaluable patients compared to the 
25% hypothesized. The 2-year FFP was 25.5% (95% CI: 14.4–36.7%), and biochemical failure 
rate was 64.4% (95% CI: 50.5–75.2%). Samarium-153 was well tolerated, with 16/60 Grade 3–4 
hematologic AEs and no Grade 5 hematologic AEs. RT was also well tolerated, with no Grade 3–5 
acute RT-related AEs, and 1 Grade 3–4 and no Grade 5 late RT-related AEs.
Conclusion: Trial NRG Oncology RTOG 0622 did not meet its primary endpoint of PSA 
response, although the regimen of Samarium-153 and salvage EBRT was well tolerated. Although 
the toxicity profile supports study of Samarium-153 in high-risk disease, it may not be beneficial 
in men receiving EBRT.
Summary
Trial NRG Oncology RTOG 0622 is a single-arm Phase II trial of men with high-risk prostate 
cancer after radical prostatectomy, enrolled at PSA failure but without clinical evidence of osseous 
metastases, who received Samarium-153 followed by salvage prostatic fossa radiation. Although 
this trial did not meet its primary endpoint of PSA response, it demonstrated the safety and 
tolerability of this regimen. The latter finding may support further use of Samarium-153 in high-
risk, non-metastatic cases after radical prostatectomy.
Keywords
Prostate cancer; radical prostatectomy; Samarium-153; salvage radiation; PSA failure
Introduction
Men with prostate cancer who undergo radical prostatectomy (RP) continue to represent a 
challenging cohort for oncologic management, as one-third will eventually develop 
biochemical failure.1 A significant proportion of biochemical recurrences lead to clinically-
evident distant metastases at a median of 8 years after PSA failure, followed by death from 
prostate cancer at a median of 5 years after the onset of distant metastases.2 Thus, there has 
been significant interest in expanding the repertoire of treatment options for high-risk but not 
yet metastatic men after RP, with the rationale that aggressive treatment of this cohort may 
reduce the proportion of men who will eventually develop metastases and die of prostate 
cancer.
When metastatic disease does develop in prostate cancer, it is known that the vast majority 
involve bony metastases, and many men who die of metastatic prostate cancer have bone-
only metastases. The extent of disease based on bone scans has been shown to correlate with 
clinical outcomes.3,4 Thus, aggressive control of bony metastases represents an important 
goal for metastatic prostate cancer.
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Over the years, multiple radionuclide conjugates have been tested and shown to be 
efficacious in the palliation of bone metastases.5 These include the beta emitters 
strontium-89 chloride6 and samarium-153 lexidronam,7 and more recently the alpha emitter 
radium-223 dichloride.8 Samarium-153 (Sm-153) is a beta emitter with an average beta 
particle energy of 233keV and a physical half-life of 46.3 hours. This radionuclide is 
chelated to lexidronam, also known as ethylene diamine tetramethylene phosphonate 
(EDTMP), and is marketed as Quadramet. Sm-153 has been shown to have an affinity for 
bone, specifically in regions of bone turnover in association with hydroxyapatite. In the 
setting of metastatic disease, Sm-153 has been shown to preferentially accumulate in blastic 
lesions compared to normal bone by a 5-fold ratio.
Trial NRG Oncology RTOG 0622 was designed to test the hypothesis that administration of 
Quadramet in the post-RP setting with documented PSA failure, but clinically and 
radiographically without evidence of non-nodal metastatic involvement, may help to target 
occult micrometastatic osseous disease, thus conferring an advantage in prostate cancer 
control compared with standard-of-care salvage radiation therapy alone. Here, we report the 
key findings in the first published report of this trial.
Patients and Methods
Trial Overview and Key Enrollment Criteria
Trial NRG Oncology RTOG 0622 is a single-arm phase II clinical trial that enrolled men 
with histologically-confirmed prostate cancer who underwent RP with pT2-T4, N0–1, M0 
disease and had an elevated post-RP PSA, to receive Sm-153 (Quadramet; Cytogen 
Corporation) followed by salvage external beam radiation therapy (EBRT) to the prostatic 
fossa. Postoperative PSA obtained within 4 weeks of study registration was required to meet 
at least one of the following criteria: (1) PSA >1.0ng/mL (2) PSA >0.2ng/ml if Gleason 
score of 9–10; or (3) PSA >0.2ng/ml if N1. All patients were required to have a whole body 
bone scan that was negative for osseous metastases within 4 months of study registration, as 
well as abdominal imaging negative for metastases within 6 months of registration. Patients 
with prior pelvic radiotherapy for any indication and/or prior chemotherapy for prostate 
cancer were excluded. In addition, patients who received androgen-deprivation therapy 
(ADT) within the preceding 3 months were excluded.
Signed informed consents were obtained from all patients at the time of study enrollment. 
The use of drugs in this protocol met the criteria for IND exemption under Title 21 CFR 
312.2(b). This trial was approved by institutional review boards at the respective study sites.
Protocol Treatment
Within two weeks of registration, patients received Sm-153 as a single intravenous infusion 
at a dose of 2.0mCi/kg. This dose was calculated to deliver an effective bone surface 
radiation dose of 50.0Gy, which was the maximum tolerated dose (MTD) on a prior phase I 
trial.9
Twelve weeks following Samarium-153 administration, all patients then proceeded to 
receive salvage EBRT to the prostatic fossa. For the EBRT component, all patients were 
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required to undergo CT simulation and were treated with either three-dimensional conformal 
radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) technique. 
Clinical target volume (CTV) was defined to include the prostatic fossa, extending from the 
seminal vesicle stump to the urethral-vesicular junction and limited laterally by the body of 
the ischium and pelvic musculature. Pelvic nodal irradiation was not offered on this trial. 
The CTV was expanded by 4–10mm to define the planning target volume (PTV). EBRT 
dose was prescribed to 64.8–70.2Gy (36–39 daily fractions of 1.8Gy, delivered 5 days per 
week over 7–8 weeks). ADT was not allowed on this trial.
Patients who did not respond to therapy were initiated on salvage ADT, consisting of 
gonadotropin-releasing hormone (GnRH) receptor agonist (Zoladex (goserelin) or Lupron 
(leuprolide)) with or without an antiandrogen (Casodex (bicalutamide) or Eulexin 
(flutamide)).
Statistical Analysis
The primary objective of this study was to assess the PSA response following Sm-153 
administration, where the PSA response was defined as a 30% decline within 12 weeks 
compared to baseline. It was expected that ≤10% of patients not treated with Sm-153 would 
have a PSA response and therefore hypothesized that Sm-153 would improve the proportion 
of patients with a PSA response to ≥25%. Using Fleming’s Multiple Testing procedure10 
with a significance level of 0.019, 69 patients are required for 91% statistical power.
The secondary objectives were to (1) assess the completion rate for the regimen of Sm-153 
and EBRT, (2) evaluate the hematological toxicity and other adverse events (AE) at 12 and 
24 weeks, and (3) freedom from progression (FFP) rate at 2 years. The completion of 
protocol treatment, defined as receiving at least 64.8 Gy radiation after the Sm-153 injection 
will be tested using an exact test for a binomial proportion against a rate of ≤50%. The null 
hypothesis is that the proportion of patients who complete protocol treatment is ≤50% and 
the alternative is that it is 80%.
All patients were evaluated for toxicity and PSA response at 12 and 24 weeks from the 
injection of Sm-153. AEs were evaluated by the NCI Common Terminology Criteria for 
Adverse Event (CTCAE) version 3.0. The treatment-related attribution included definitely, 
probably, or possibly related to treatment. The Sm-153-related AEs were defined as (1) 
Hematologic AEs: Platelet grade 3–5, WBC grade 3–5, hemoglobin grade 3–5, and/or any 
secondary leukemia; (2) Hemorrhage/bleeding AEs: GI bleeding (anus, rectum) grade 3–5, 
and/or GU bleeding (bladder, prostate, urethra) grade 3–5; and (3) Sm-153-related grade 5 
AE prior to radiation treatment (RT). Sm-153-related AEs were defined as those occurring 
within 12 weeks of the injection and prior to the start of RT. Acute RT-related AEs were 
defined as those occurring <90 days from the end of RT, and late RT-related AEs were 
defined as those occurring ≥90 days from the end of RT. Multivariate logistic regression was 
used to model the distribution of treatment-related AEs. Clinical T-stage, baseline PSA, 
Gleason score, and age were identified as predictor variables for statistical analyses. Both 
unadjusted and adjusted odds ratios and the respective 95% confidence intervals were 
computed.
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Progression was defined as biochemical (PSA) failure at any time for 2 years after prostatic 
fossa RT, initiation of systemic therapy, or clinical failure. PSA failure was defined as a rise 
of ≥0.2ng/ml above the nadir PSA after completion of salvage RT followed by another 
higher value or a continued rise in the serum PSA despite RT. Local failure was defined as 
the development of a new palpable abnormality in the prostate bed after enrollment in the 
protocol. Regional failure was defined as radiographic evidence (CT or MRI) of 
lymphadenopathy (lymph node size ≥ 1.5 cm) in a patient without the diagnosis of a 
hematologic/lymphomatous disorder associated with adenopathy. Distant metastasis was 
defined as evidence of hematogenous spread documented by imaging (e.g., bone scan, CT, 
MRI). Freedom from progression (FFP) was measured from the date of registration to date 
of progression, including death from any cause, or last known follow-up date. FFP was 
estimated using the Kaplan-Meier method.11 Time to progression was measured from the 
date of registration to date of progression or last known follow-up. Patients who died 
without progression were treated as a competing risk. Time to local, regional, and distant 
failure was measured from the date of registration to the date of failure or last known follow-
up. Patients who died without a failure were treated as a competing risk. The cumulative 
incidence approach was used to estimate the median time to progression, time to local 
failure, time to regional failure, and time to distant failure to account for the competing risk 
of death.12
Results
Patient demographics and trial compliance
This study enrolled 67 patients, of whom 5 were ineligible. The reasons for ineligibility 
included absolute neutrophil count and platelets not within protocol criteria (n=1), bone scan 
not done within protocol criteria (n=3), and no abdominal imaging done prior to registration 
(n=1). Among the 62 eligible patients, 2 withdrew consent early in the study, and AE 
information was available for the remaining 60 patients. Patient demographics are shown in 
Table 1. The median age of enrolled patients was 65 (interquartile range 60–69). Most 
patients were white (83.9%) and were not Hispanic or Latino (88.7%). The majority of 
enrolled patients had Zubrod performance status of 0 (83.9%). Most cases had a T stage of 
pT3 (75.8%) and an N stage of pN0 (87.1%). Most patients had a post-operative PSA 
>1ng/ml (56.5%), and the majority had Gleason scores of 8–10 (56.5%). The median post-
operative PSA was 1.99.
Most of the patients received treatment per protocol, or with an acceptable variation for 
tumor volume contouring score (90.0%), organ at risk contouring score (90%), and tumor 
volume dose volume analysis score (81.7%). Most patients (57/60; 95.0%) received Sm-153 
and at least 64.8Gy of RT. This was significantly more than the hypothesized 50% 
(p<0.0001).
Tolerability and toxicity of regimen
Overall toxicity information is presented in Table 2A and Supplemental Table 1. There was 
only one grade 5 AE (non-hematologic) that occurred 49 days from the Sm-153 injection, 
but was not considered to be related to treatment.
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Sm-153-related AEs are presented in Table 3. There were 16/60 patients (26.7%) that 
experienced grade 3–5 Sm-153-related AEs. Among hematologic AEs, 15 patients 
experienced at least one Grade 3 AE (8 Grade 3 leukopenia and 10 Grade 3 
thrombocytopenia) and 1 patient experienced Grade 4 thrombocytopenia. No Grade 5 
hematologic AEs were noted. In addition, there were no observed hemorrhage/bleeding AEs. 
None of the pre-specified variables (age, baseline PSA, clinical T-stage, or Gleason score) 
were significantly associated with occurrence of Sm-153-related AEs (Table 4A). There 
were 4 patients who experienced Grade 4 hematologic events with any relationship to 
protocol treatment. One patient experienced both Grade 4 neutropenia and Grade 4 
thrombocytopenia.
There were 36 patients with acute RT-related AEs (Table 2B, Supplemental Table 2). Only 
one Grade 3 AE (non-hematologic) unlikely related to the treatment was noted during the 
acute RT period, and there were no Grade 4–5 AEs during this period. Based on logistic 
regression models, none of the predictor variables specified in the protocol (age, baseline 
PSA, clinical T-stage, or Gleason score) were significantly associated with acute RT-related 
toxicity (Table 4B). There were 35 patients who experienced AEs during the late RT period, 
although only one (2.9%) Grade 3 AEs and no Grade 4–5 late RT-related AEs noted (Table 
2C, Supplemental Table 3).
PSA response
All PSA values within 12 weeks from the injection that were also prior to the start of RT 
were considered. Of the 60 evaluable patients, only 52 had PSA values in the appropriate 
time frame, with 5 having only having values after the start of RT, 3 had values only after 12 
weeks from the injection. With the reduced sample size of 52 evaluable patients, this study 
had only 78% power. Using this reduced power and sample size, at least 11 patients with 
≥30% decline would be required to reject the null hypothesis. Seven of 52 patients (13.5%) 
achieved ≥30% decline in PSA values from their respective pre-treatment baseline values. 
However, most patients experienced a PSA increase over time (mean increase of 0.177, 
standard deviation=0.479). Out of the 30 patients with a post-operative PSA > 1.0ng/mL, 4 
(13.3%) achieved ≥30% decline in PSA. For the 22 patients with a post-operative PSA > 
0.2ng/mL and nodal disease or a Gleason score of 9 or 10, 3 achieved ≥30% decline in PSA 
(13.6%). By logistic regression, none of the specified predictor variables of age, baseline 
PSA, clinical T-stage, or Gleason score were significantly associated with PSA response 
(Table 4C).
Biochemical and radiographic failure events
The median follow-up was 4.0 years for all patients (n=60), and 4.0 years for all living 
patients (n=50). There were 44 failure events, among which 38 were biochemical failures, 2 
were local failures, 2 were regional failures, and 13 were distant failures (Table 5). The 2-
year estimate for FFP was 25% (95% confidence interval [CI]: 14–37%). Time to 
progression showed a rate of 74.5% (95% CI: 60.9–83.9%) at 2 years. Biochemical failure 
showed a rate of 64.4% (95% CI: 50.5–75.2%) at 2 years.
Valicenti et al. Page 6






















Here we report the results of Trial NRG Oncology RTOG 0622 at a median follow up of 4.0 
years. This trial was designed to test the hypothesis that administration of Sm-153 
lexidronam in prostate cancer patients with documented PSA failure after RP, but without 
evidence of non-nodal metastatic involvement, may confer an advantage in prostate cancer 
control compared with standard-of-care salvage RT alone. As noted above, the study 
unfortunately did not meet its primary endpoint of PSA control. Among the 52 analyzable 
patients, only 7 (13.5%) achieved a PSA response after Sm-153. However, it should be noted 
that the regimen of Sm-153 and prostatic fossa RT was well tolerated: 15/60 patients 
experienced Grade 3 hematologic AEs, 1/60 patients experienced Grade 4 hematologic AE 
(thrombocytopenia), and no patients experienced Grade 5 hematologic AEs. The single 
Grade 5 AE (non-hematologic) occurring 49 days after Sm-153 injection was not considered 
to be treatment-related. RT was also well tolerated, with no Grade 3–5 acute RT-related AEs, 
and one Grade 3 no Grade 4–5 late RT-related AEs.
Given the limited PSA response on this trial, the current evidence does not support the use of 
Sm-153 with salvage RT in this particular high-risk post-RP cohort, prior to the development 
of radiographically-evident osseous metastases. The most likely explanation for the results is 
that Sm-153 is not effective in treating micrometastatic osseous lesions. It is possible that 
there was insufficient bone turnover at micrometastatic sites to allow sufficient localization 
of the radionuclide. Even if Sm-153 could localize appropriately to these sites, early prostate 
cancer metastases may somehow be relatively radioresistant, thus not allowing as much of a 
therapeutic benefit as would be expected given the relatively low disease burden. Future 
trials are likely to use Rm-223 rather than Sm-153 and in retrospect may have been the 
preferred agent for this trial. It should be noted that 13/60 patients did eventually develop 
distant failures in follow up (estimated 2-year distant failure rate of 22.0%, with 95% CI of 
12.4–33.3%). Although we do not have detailed information regarding the sites of distant 
failure, it is almost certainly the case that most of these events were osseous metastases. 
Altogether, the data suggest that these patients do have a significant risk of distant failure, 
but the timing of treatment is critical as their risk of disease progression could not be 
mitigated by the current strategy. While effective in treating clinically evident osseous 
metastases, Sm-153 appears to be ineffective at earlier time points and unlike Ra-223 it has 
never been demonstrated to improve survival in men with advanced metastatic prostate 
cancer. It should be noted that this study was designed as a single-arm Phase II trial without 
ADT, with a relatively high pre-treatment PSA of >2ng/ml in the majority of men. In this 
regard, it is not clear which contemporary post-RP series would offer the most appropriate 
comparison of biochemical and clinical control outcomes.
In patients with PSA failure after RP, the benefits of salvage radiation to the prostatic fossa 
have already been well documented from prospective trials with long-term follow up, as well 
as multiple retrospective series. The three randomized trials of post-RP radiation in patients 
with one or more high-risk features (extracapsular extension, seminal vesicle involvement, 
and/or positive margins) have demonstrated significant improvements in clinical endpoints 
including biochemical control,13–15 progression-free survival,14,15 metastasis-free survival,
13
 and overall survival.13 In the setting of early biochemical failure as defined by a rising 
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PSA, retrospective evidence has supported the benefit of salvage radiation in improving 
prostate cancer-specific survival.16
Of note, ADT was not included as part of the initial management of patients on Trial NRG 
Oncology RTOG 0622. However, there has been mounting evidence of the importance of 
ADT in the management of post-RP biochemical failure. NRG Oncology RTOG 9601 
(NCT00002874) showed improved overall survival and freedom from subsequent 
biochemical failure with the inclusion of ADT to salvage EBRT in a similar high-risk post-
RP cohort.17 The recently published Groupe d'Etudes des Tumeurs Uro-Génitales 
(GETUG)-16 trial (NCT00423475) showed that inclusion of short-term Goserelin to salvage 
RT conferred an improvement in progression-free survival, although no significant overall 
survival benefit was found.18 Regarding the subset of post-RP patients who are found to be 
node-positive (8/62 of the patients enrolled on Trial NRG Oncology RTOG 0622), 
randomized evidence from ECOG 3886 has convincingly demonstrated a significant OS 
benefit with the utilization of immediate ADT,19 so it is likely that this cohort of patients 
would be offered ADT in the early post-RP period.
The timing of further intervention after RP is a topic of multiple ongoing trials, although 
there are multiple lines of retrospective evidence supporting improved clinical outcomes 
with earlier intervention.20,21 Early vs. deferred salvage radiation is currently the subject of 
several ongoing trials, including Trans-Tasman Radiation Oncology Group (TROG) 
Radiotherapy – Adjuvant Versus Early Salvage (RAVES) 08.03 (NCT00860652), 
GETUG-17 (NCT00667069), and Radiotherapy and Androgen Deprivation In Combination 
After Local Surgery (RADICALS; Medical Research Council PR10; NCT00541047). The 
results of these studies are eagerly awaited as they will help to guide future practice in the 
setting of high-risk prostate cancer patients after RP, including those who might have not yet 
experienced biochemical failure.
In summary, the results of Trial NRG Oncology RTOG 0622 demonstrate that Sm-153 does 
not confer a significant PSA benefit when given with salvage prostatic fossa radiation in the 
setting of high-risk post-RP patients with biochemical failure, but no clinically evident 
osseous metastases. While a negative finding, the relatively good toxicity profile of this 
agent does leave open the possibility of other approaches that may be able to take advantage 
of its utility in treating osseous metastases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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    Median 65
    Min - Max 49 - 83
    Q1 - Q3 60 - 69
Race
    Asian 3 (4.8%)
    Black or African American 7 (11.3%)
    White 52 (83.9%)
Ethnicity
    Hispanic or Latino 3 (4.8%)
    Not Hispanic or Latino 55 (88.7%)
    Unknown 4 (6.5%)
Zubrod Performance Status
    0 52 (83.9%)
    1 10 (16.1%)
T Stage
    pT2 15 (24.2%)
    pT3 47 (75.8%)
N Stage
    pN0 54 (87.1%)
    pN1 8 (12.9%)
Post-Operative PSA
    Post-operative PSA > 1.0 35 (56.5%)
    Post-operative PSA > 0.2 and with a surgical tumor Gleason of 9 or 10 25 (40.3%)
    Post-operative PSA rising > 0.2 with nodal disease 2 (3.2%)
Gleason
    2–6 4 (6.5%)
    7 23 (37.1%)
    8–10 35 (56.5%)
Q1 = first quartile; Q3 = third quartile.
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Table 2.




1 2 3 4 5
A. Overall Treatment Toxicity
Blood/bone marrow 10 17 17 5 0
Coagulation 0 1 0 0 0
Constitutional symptoms 22 8 0 0 0
Dermatology/skin 4 1 0 0 0
Endocrine 8 1 0 0 0
Gastrointestinal 20 5 1 0 0
Hemorrhage/bleeding 4 0 0 0 0
Infection 0 1 0 0 0
Metabolic/laboratory 7 0 0 0 0
Musculoskeletal/soft tissue 1 1 0 0 0
Neurology 0 2 0 0 0
Pain 7 2 0 0 0
Renal/genitourinary 24 12 0 0 0
Sexual/reproductive function 2 6 0 0 0
B. Acute Radiotherapy Toxicity
Blood/bone marrow 7 5 0 0 0
Constitutional symptoms 15 4 0 0 0
Dermatology/skin 3 1 0 0 0
Endocrine 1 1 0 0 0
Gastrointestinal 11 5 0 0 0
Hemorrhage/bleeding 1 0 0 0 0
Infection 0 1 0 0 0
Metabolic/laboratory 2 0 0 0 0
Musculoskeletal/soft tissue 1 0 0 0 0
Neurology 1 1 0 0 0
Pain 6 0 0 0 0
Renal/genitourinary 21 4 0 0 0
Sexual/reproductive function 1 1 0 0 0
C. Late Radiotherapy Toxicity
Blood/bone marrow 3 1 0 1 0
Constitutional symptoms 8 1 0 0 0
Dermatology/skin 2 0 0 0 0
Endocrine 6 1 0 0 0
Gastrointestinal 9 2 0 0 0
Hemorrhage/bleeding 2 0 0 0 0
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Category
Grade
1 2 3 4 5
Musculoskeletal/soft tissue 0 1 0 0 0
Neurology 0 1 0 0 0
Pain 1 1 0 0 0
Renal/genitourinary 13 7 0 0 0
Sexual/reproductive function 1 4 0 0 0
Includes adverse events where relationship to protocol treatment is missing.
Adverse events were graded with CTCAE version 3.0.
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Table 3.
Number of Patients with an Adverse Event by Category, Term, and Grade Samarium 153 Toxicity at 12 weeks 
Definitely, Probably, or Possibly Related to Treatment (n=16)
Category Term Grade
1 2 3 4 5
BLOOD/BONE MARROW 13 17 15 1 0
    Hemoglobin decreased 25 0 0 0 0
    Leukopenia 12 17 8 0 0
    Platelet count decreased 19 15 10 1 0
HEMORRHAGE/BLEEDING 0 0 0 0 0
TREATMENT -RELATED GRADE 5 AE N/A N/A N/A N/A 0
Includes adverse events where relationship to protocol treatment is missing.
Adverse events were graded with CTCAE version 3.0.
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Table 4.
Logistic Regression Estimates




95% Wald Confidence Limits
A. Samarium-153 Related AEs at 12 weeks [1]
Age 0.03 0.05 0.50 1.03 0.94 1.13
Baseline PSA −0.16 0.14 0.26 0.85 0.64 1.13
Clinical T-stage (pT2 vs. pT3) 0.31 0.36 0.39 1.85 0.46 7.53
Gleason score (<8 vs. 8–10) −0.19 0.34 0.58 0.69 0.18 2.62
B. Acute RT related AEs [3]
Age −0.02 0.04 0.54 0.98 0.90 1.06
Baseline PSA 0.02 0.07 0.82 1.02 0.88 1.17
Clinical T-stage (pT2 vs. pT3) 0.11 0.33 0.74 1.25 0.35 4.52
Gleason score (<8 vs. 8–10) −0.27 0.29 0.35 0.59 0.19 1.81
C. PSA Response [3]
Age 0.09 0.06 0.15 1.09 0.97 1.24
Baseline PSA 0.09 0.08 0.26 1.09 0.94 1.27
Clinical T-stage (pT2 vs. pT3) −0.23 0.63 0.72 0.63 0.05 7.53
Gleason score (<8 vs. 8–10) −0.33 0.50 0.51 0.52 0.07 3.70
[1]Outcome variable: Samarium-153 Related AE (Yes/No)
[2]Outcome variable: Acute RT related AE (Yes/No)
[3]Outcome variable: PSA response (>30% change,<=30% change )
Bolded levels are reference levels
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Table 5.
2 Year Estimates (n=60)
Estimate (%) 95% CI (%) Number of Failures
Freedom From Progression* 25.5 (14.4, 36.7) 44
Time to Progression§ 74.5 (60.9, 83.9) 44
Biochemical Failure§ 64.4 (50.5, 75.2) 38
Distant Failures§ 22.0 (12.4, 33.3) 13
Regional Failure§ 3.4 (0.6, 10.4) 2
Local Failures§ 3.4 (0.6, 10.5) 2
*
Estimated using Kapan Meier method
§
Estimated using cumulative incidence method
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